Optimizing Identification and Molecular Testing for ALK-Positive NSCLC

In this segment, faculty discuss the biology of ALK rearrangements and their role in driving tumor growth in non-small cell lung cancer (NSCLC). The panel reviews clinical and demographic characteristics commonly associated with ALK-positive disease and examines the rationale for broad molecular testing regardless of patient presentation. Discussion focuses on testing strategies used to identify ALK rearrangements, including next-generation sequencing and liquid biopsy approaches, as well as practical considerations related to tissue availability and turnaround time. The faculty also address how comprehensive molecular profiling supports treatment planning and helps identify patients who may be eligible for targeted therapies. Throughout the conversation, panelists share perspectives on integrating biomarker testing into routine clinical practice and ensuring timely identification of actionable alterations in advanced NSCLC.